Pharmaceutical Reports

2018 Glaucoma Pharmaceuticals Report: A Global Market Analysis for 2017 to 2023

Our report on the glaucoma pharmaceuticals market, now in its fifth edition, is a leading industry source for accurate and relevant information on all aspects of the glaucoma pharmaceuticals market. The glaucoma pharmaceuticals market is one of the largest and most complex market segments in ophthalmology with a variety of drug classes, as well as proprietary and generic versions of many drugs. Current ocular hypotensive medication classes used to treat glaucoma were developed 20 years ago or more, and generic versions of these medications are now in widespread use.

Additional DescriptionMore Details

Market Scope’s 2018 Glaucoma Pharmaceutical report features:

• New and updated estimates of glaucoma populations around the world
• Analysis of two new classes glaucoma therapeutics launched in the US in 2018: nitric oxide-donating compounds and rho kinase (ROCK) inhibitors
• Expanded discussions of genetics, gene therapies, stem cell therapies, and sustained-release devices

The report analyses 61 marketed medications and differences in their popularity around the world, 16 pipeline agents in development, 22 discontinued drug candidates, 10 clinical stage alternative drug delivery platforms, 10 preclinical alternative drug delivery platform programs, and another nine university-based drug delivery research programs.

It includes new market forecasts based on updated information from user surveys and price surveys.

ABOUT THE AUTHOR


Four Disease Categories Are Analyzed In This Report:


Primary Open-angle Glaucoma (POAG), Primary Angle-closure Glaucoma (PACG), Other Secondary OAG and ACG, and Ocular Hypertension (OHT)

Each Market Segment Includes:
An Analysis of Market Competitors and Five‐Year Forecasts for Market Performance

Also Included in This Report:
• Overview of Glaucoma
• Prevalence of Glaucoma and Diagnosed Cases
• Glaucoma Care Providers
• Diagnosing Glaucoma
• Treating Glaucoma
• Glaucoma Medications in the Marketplace
• Development Pipeline for Glaucoma Rx
• Adjunctive Drugs Used in Glaucoma Surgery
• 25 Company Profiles
• 54 Color Tables and 33 Color Figures

This edition of our 2018 Glaucoma Pharmaceutical Report was published in June 2018. The report is printed in color and spiral bound for easy reading. Two licensing types are available for this report. The price of the report is $6,800 for a SINGLE USER LICENSE (an electronic PDF copy and/or an additional paper copy is available for use within your company for an additional $500 and $300, respectively). The price of the ENTERPRISE LICENSE is $10,200 (includes a printable PDF and supplemental Excel file with all the tables and figures in the report).

*Note: The PDFs are not downloadable: PDF copies of reports are manually prepared and emailed to the account listed on the order within 24 hours. Please call our office for immediate assistance or to discuss purchasing additional copies of a report at (314) 835-0600.

Market Scope’s industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective ophthalmic experience and each data point is driven by a combination of sources, including the following:

• Our proprietary global disease population and demographic models
• Twenty years and counting of ophthalmologist survey data
• Analysis of company published financial reports
• Focused coverage of ophthalmic scientific research, business news and other activities
• Attendance and participation in major, worldwide ophthalmic meetings
• Interviews and long-standing relationships with company executives and practicing ophthalmologists

Product Options

Price: from $6,800.00

Loading Updating cart...

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022

In this report, we examine dry eye syndrome’s etiology, diagnosis, and treatment; the prevalence of dry eye; Rx therapeutics for dry eye; over-the-counter lubricants; punctum plugs; and additional dry eye procedures and products. The report also includes profiles of the companies that make and distribute dry eye products. Our analytic categories are the US, Western Europe, Japan, Other Wealthy Nations, China, India, Latin America, and Rest of World (a mix of developing nations and underdeveloped countries).

Additional DescriptionMore Details

What’s new: Market Scope expects the global dry eye treatments market to total $3.7 billion in 2017 and reach $4.9 billion in 2022. The highest rate of growth is expected to occur in China, India, and other emerging markets where we forecast double-digit annual growth rates due to aging populations, increasing wealth, and improving access to health care. In 2016, the US saw its first new pharmaceutical treatment in 13 years hit the ground running, with Shire’s Xiidra (lifitegrast). Allergan, maker of Restasis, gained US clearance in 2017 for a new device, a neurostimulator, called TrueTear.

ABOUT THE AUTHOR

Our report is organized into key areas and includes:

Dry Eye Overview
Care for Dry Eye
Diagnosis of Dry Eye
Treatment Modalities for Dry Eye
Prevalence of Dry Eye
The Global Dry Eye Treatment Market
The Rx Product Market Segment
Recent Rx Development Pipeline
The Rx Product Market Segment
Over-the-counter Market Segment
Procedure Market Segment
Punctum Plug Market Segment
Dry Eye Procedures
Additional Dry Eye Products
Dry Eye Organizations

VIEW THE TABLE OF CONTENTS FOR THIS REPORT.

The data included in our reports is based on surveys of ophthalmologists, reviews of clinical data, interviews with company executives, and analysis of company financial data.

Our 2017 Dry Eye Products Report is printed in color and spiral bound for easy reading. Two licensing types are available for this report. The price of the report is $4,500 for a SINGLE USER LICENSE (an electronic PDF copy and/or an additional paper copy is available for use within your company for an additional $500 and $300, respectively). The price of the ENTERPRISE LICENSE is $ 6,750 (includes a printable PDF and supplemental Excel file with all the tables and figures in the report).

*Note: The PDFs are not downloadable: PDF copies of reports are manually prepared and emailed to the account listed on the order within 24 hours. Please call our office for immediate assistance or to discuss purchasing additional copies of a report at (314) 835-0600.

Product Options

Price: from $4,500.00

Loading Updating cart...

2017 Retinal Pharmaceuticals and Biologics Report: A Global Market Analysis for 2016 to 2022

Our report on the retinal pharmaceuticals and biologics market is in its eighth edition. It is a leading industry source for accurate and relevant information on all aspects of the market. We cover prevalence and forecasts for retinal diseases and conditions. We discuss therapeutic approaches and mechanisms of action under investigation. We discuss the market dynamics for currently commercialized products and the rich and crowded pipeline of investigational therapies. We review patient-based economic issues and reimbursement and analyze treatment patterns and trends. We also forecast product demand in units and dollars, and we analyze market shares by product category.

What's New? The 2017 Retinal Pharmaceuticals and Biologics Report has significant enhancements from previous reports, with updated estimates of the prevalence of diabetes and new extended analysis and discussions of diseases.

Additional DescriptionMore Details

We analyze worldwide markets using the following geographic/economic categories: the US, Western Europe, Japan, Other Wealthy Nations, China, India, Latin America and Rest of World. This report includes market data for 2016, and we forecast market performance through 2022.

Market Scope’s 2017 Retinal Pharmaceuticals and Biologics Report provides in-depth coverage of current and future pharmaceuticals and biologics used in treating retinal diseases.

ABOUT THE AUTHOR


Eight Categories Are Analyzed In This Report:

VEGF Inhibitors, PDGF Inhibitors, Neuroprotectors, Complement Cascade Inhibitors, Visual Cycle Modulators, Gene Therapies, Corticosteroids, and Other Mechanisms of Action

Each Market Segment Includes:
An Analysis of Market Competitors and Five‐Year Forecasts for Market Performance

Also Included in This Report:
• Review of Retinal Diseases and Treatments
• Symptoms, Diagnosis, and Treatment of AMD
• Diagnosis and Management of Diabetic Retinopathy and Macular Edema
• An Overview of Other Retinal Diseases and Conditions
• Epidemiology of Retinal Disease
• Patient Economics and Reimbursement
• Retina Specialists and Training
• Current Retinal Pharmaceuticals in the Marketplace
• 27 Company Profiles
• 41 Color Tables and 47 Color Figures

2017 Retina Pharma Graphic

VIEW THE TABLE OF CONTENTS OF THIS REPORT

The 2017 Retinal Pharmaceuticals and Biologics Report: A Global Market Analysis for 2016 to 2022 will be released in October 2017. The report is printed in color and spiral bound for easy reading. Two licensing types are available for this report. The price of the report is $6,800 for a SINGLE USER LICENSE (an electronic PDF copy and/or an additional paper copy is available for use within your company for an additional $500 and $300, respectively). The price of the ENTERPRISE LICENSE is $10,200 (includes a printable PDF and supplemental Excel file with all the tables and figures in the report).

*Note: The PDFs are not downloadable: PDF copies of reports are manually prepared and emailed to the account listed on the order within 24 hours. Please call our office for immediate assistance or to discuss purchasing additional copies of a report at (314) 835-0600.


Market Scope’s industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective ophthalmic experience and each data point is driven by a combination of sources, including the following:


• Our proprietary global disease population and demographic models
• Twenty years and counting of ophthalmologist survey data
• Analysis of company published financial reports
• Focused coverage of ophthalmic scientific research, business news and other activities
• Attendance and participation in major, worldwide ophthalmic meetings
• Interviews and long-standing relationships with company executives and practicing ophthalmologists

Product Options

Price: from $6,800.00

Loading Updating cart...
LoadingUpdating...

Shopping Cart

Your shopping cart is empty
View all of the reports

Note: Report PDFs are not downloadable

PDF copies of reports are manually prepared and emailed to the account listed on the order within 24 hours. Please call our office for immediate assistance or to discuss purchasing additional copies of a report at (314) 835-0600.